Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Consolidated Net Income (2016 - 2026)

Assembly Biosciences has reported Consolidated Net Income over the past 11 years, most recently at $22.1 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 313.74% year-over-year to $22.1 million; the TTM value through Dec 2025 reached -$6.1 million, up 84.76%, while the annual FY2025 figure was -$6.1 million, 84.76% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $22.1 million at Assembly Biosciences, up from -$9.2 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $22.1 million in Q4 2025 and troughed at -$62.8 million in Q4 2021.
  • A 5-year average of -$16.7 million and a median of -$15.7 million in 2023 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: plummeted 461.45% in 2021 and later surged 313.74% in 2025.
  • Year by year, Consolidated Net Income stood at -$62.8 million in 2021, then surged by 64.33% to -$22.4 million in 2022, then soared by 51.05% to -$11.0 million in 2023, then increased by 5.72% to -$10.3 million in 2024, then soared by 313.74% to $22.1 million in 2025.
  • Business Quant data shows Consolidated Net Income for ASMB at $22.1 million in Q4 2025, -$9.2 million in Q3 2025, and -$10.2 million in Q2 2025.